Pfiz­er's Xalko­ri fol­low-up, which smoked the old­er drug in 1st-line pa­tients, scores dou­ble win at the FDA

De­spite be­ing the first to mar­ket in ALK-pos­i­tive non-small cell lung can­cer, Pfiz­er’s Xalko­ri lan­guished on the shelf as oth­er com­peti­tors out­paced it. Now, af­ter Pfiz­er’s fol­low-up drug ab­solute­ly smoked Xalko­ri in first-line pa­tients, the FDA is tak­ing no­tice.

In one fell swoop, the agency ap­proved Lor­bre­na as a first-line treat­ment for pa­tients with anaplas­tic lym­phoma ki­nase (ALK)-pos­i­tive NSCLC and ex­tend­ed the drug’s 2018 ac­cel­er­at­ed ap­proval to a full ap­proval, Pfiz­er an­nounced on Wednes­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.